Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis

Clinical Cancer Research

Volumn 3, Issue 6, 1997, Pages 963-972

  Uslu, Ruchan ^a   Borsellino, Nicolò ^a   Frost, Patrick ^a   Gárban, Hermes ^a   Ng, Chuen Pei ^a   Mizutani, Yoichi ^a   Belldegrun, Arie ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CISPLATIN; CYTOTOXICITY, IMMUNOLOGIC; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; FAS LIGAND PROTEIN; HUMANS; IMMUNOTHERAPY; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030964237     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics 1995. CA: A Cancer Journal for Clinicians, 45: 8-30, 1995.
2. Huggins, C., Stevens, R. E., and Hodges, C. L. Studies on prostatic cancer. II. The effect of castration on clinical patients with carcinoma of the prostate. Arch. Surg., 43: 209-223, 1941.
3. Mahler, C., and Denis, L. Management of relapsing disease in prostate cancer. Cancer (Phila.), 70: 329-334, 1992.
4. Yagoda, A., and Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (Phila.), 71: 1098-1109, 1993.
5. Gosland, M., Lum, B., Schimmelpfennis, J., Baker, J., and Doukas, M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy, 16: 16-39, 1996.
6. Woogd, T. E., Vansterkenburg, E. L. M., Wilting, J., and Janssen, L. H. M. Recent research on the biological activity of suramin. Pharmacol. Rev., 45: 177-203, 1993.
7. Eisenberser, M. A., and Reyno, L. M. Suramin. Cancer Treat. Rev., 20: 259-273, 1994.
8. Van Ravenswaay Claasen, H. H., and Fleuren, G. J. The influence of combination chemotherapy on antigen expression in ovarian cancer. Gynecol. Oncol., 58: 16-23, 1995.
9. Safrit, J. T., and Bonavida, B. Sensitivity of resistant human tumor cell lines to TNF and Adriamycin used in combination: correlation between downregulation of TNF-mRNA induction and overcoming resistance. Cancer Res., 52: 6630-6637, 1992.
10. Safrit, J. T., Berek, J. S., and Bonavida, B. Sensitivity of drug resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-α) and doxorubicin. Failure of the combination to modulate the MDR phenotype. Gynecol. Oncol., 48: 214-220, 1992.
11. Mizutani, Y., and Bonavida, B. Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-α. Cancer (Phila.), 72: 809-818, 1993.
12. Charak, B. S., Brown, E. G., and Mazumder, A. Induction of antisense effect by treatment with cyclosporine A plus interferon-γ after chemotherapy: role of cytotoxic cells. J. Immunother., 17: 131-140, 1995.
13. Nagata, S. Fas and Fas ligand: a death factor and its receptor. Adv. Immunol., 57: 129-144, 1994.
14. Trauth, B. C., Klas, C., Peters, A. M. J., Matzky, S., Moller, P., Falk, W., Debatin, K-M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-304, 1989.
15. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169: 1747-1756, 1989.
16. Ogasawara, J., Watanabe-Fukanaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of anti-Fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
17. Krammer, P. H., Behrmann, I., Bier, V., Daniel, P., Dhein, J., Falk, M. H., Garcin, G., Klas, C., Knipping, E., Lucking-Famira, K. M., Matzku, S., Oehm, A., Richards, S., Trauth, B. C., Bornkamm, G. W., Falk, W., Moller, P., and Debatin, K. M. Apoptosis in APO-1 system. In: L. D. Tomei and F. O. Cope (eds.), Apoptosis: The Molecular Basis of Cell Death, pp. 87-99. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1991.
18. Watanabe-Fukanaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. Lymphoproliteration disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.), 356: 314-317, 1992.
19. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169-1178, 1993.
20. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med., 177: 195-200, 1993.
21. Arase, H., Arasi, N., and Saito, T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med., 181: 1235-1238, 1995.
22. Walsh, C. M., Glass, A. A., Chiu, V., and Clark, W. R. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J. Immunol., 153: 2506-2514, 1994.
23. Darzynkiewicz, Z., Bruno, S., Del Nino, G., Gorzycca, W., Hotz, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry. Cytometry, 13: 795-808, 1992.
24. Telford, W. G., King, L. E., and Fraker, P. J. Rapid quantitation of apoptosis in pure and heterogenous cell populations using flow cytometry. J. Immunol. Methods. 172: 1-16, 1994.
25. Jewett, A., and Bonavida, B. Target-induced split anergy and apoptosis in a subset of human natural killer cells. J. Immunol. 156: 907-915, 1996.
26. Moller, P., Koretz, K., Leithasuer, F., Bruderlein, S., Henne, C., Quentmeier, A., and Krammer, P. H. Expression of APO-1 (CD95), a member of the TNF/NGF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer. 57: 371-377, 1994.
27. Berenbaum, M. C. Criteria for analyzing interactions between biologically active agents: Adv. Cancer Res., 35: 269-290, 1981.
28. Uslu, R., Jewett, A., and Bonavida, B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gynecol. Oncol., 62: 282-291, 1996.
29. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.) 348: 334-376, 1990.
30. Sato, T., Irie, S., Kitada, S., and Reed, J. C. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science (Washington DC), 268: 411-415, 1995.
31. Evan, G. I., and Littlewood, T. D. The role of c-myc in cell growth. Curr. Opin. Genet. Dev., 3: 44-49, 1993.
32. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krummer, P. H., and Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat. Med., 2: 1361-1366, 1996.
33. Martin, S. J., and Green, D. R. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit. Rev. Oncol. Hematol., 18: 137-153, 1995.
34. Mori, S., Murakami-Mori, K., Jewett, A., Nakamura, S., and Bonavida, B. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res., 56: 1874-1879, 1996.
35. Berchem, J. G., Bosseler, M., Sugars, L. Y., Voeller, H. J., Zeitlin, S., and Gelmann, E. P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735-738, 1995.
36. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
37. Ibrado, A. M., Huang, Y., Fang, G., Liu, L., and Bhalla, K. Overexpression of Bcl-2 or Bcl-XL inhibits ara-c-induced cpp32/YamA protease activity and apoptosis of human acute myeloma leukemia HL-60 cells. Cancer Res., 56: 4743-4748, 1996.
38. Chiu, U. K., Walsh, C. M., Liu, C., Reed, J. C., and Clark, W. R. Bcl-2 blocks degranulation but not Fas-based cell-mediated cytotoxicity. J. Immunol., 154: 2023-2032, 1995.
39. Lacronique, U., Mignon, A., Fabre, M., Viollet, B., Rouquet, N., Molian, T., Porteu, A., Henrion, A., Bouscary, D., Varlet, P., Joulin, V., and Kahn, A. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med., 2: 80-86, 1996.
40. Sinha, B. K., Yamazaki, H., Eliot, H. M., Schneider, E., Burner, M. M., and O'Conner, P. M. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochem. Biophys. Acta, 1270: 12-18, 1995.
41. Kleinerman, E. S., Zwelling, L. A., and Mushmore, A. V. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diammine dichloroplatinum(II). Cancer Res., 40: 3099-3102, 1980.
42. Lichtenstein, A. K., and Pende, D. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum(II) in vivo and in vitro. Cancer Res., 46: 639-644, 1985.
43. Gan, X-H., Jewett, A., and Bonavida, B. Activation of human peripheral blood monocytes by CDDP: enhanced tumoricidal activity and secretion of TNF-α. Nat. Immunity, 11: 144-155, 1992.